Clinical Trial

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Our study is aimed to evaluate the efficacy and safety of novel ADC named SHR-A1921 combined with Adebrelimab in endocrine therapy-failed HR (Hormone Receptor)-positive, HER2-negative advanced breast cancer.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06470672
Lead Sponsor Fudan University
Conditions Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Enrollment 32 participants
Start Date 2024-12
Primary Completion 2026-03 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2024-12-20